New Budget Bill Short Shrifts Science

The omnibus spending bill unveiled by US Congress this week would restore some research budgets cut by sequestration, but critics say it's not enough.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, KMCCOYThe US Congress rolled out an omnibus $1.1 trillion spending bill on Monday (January 13) that would keep the government in operation through October. The bipartisan bill, which was authored by House Appropriations Committee Chairman Harold Rogers (R-KY) and Senate counterpart Barbara Mikulski (D-MD), slates $29.934 billion in funding for the National Institutes of Health (NIH), a $1 billion increase from the agency’s sequester-wracked 2013 budget.

But this boost isn’t large enough, according to many in the research community. “The FY14 omnibus spending bill falls short of restoring funding for lifesaving National Institutes of Health (NIH) biomedical research,” said Carrie Wolinetz, president of the biomedical science advocacy group United for Medical Research, in a statement. “The proposed package won’t adequately reverse the damage done by last year’s budget sequester and ensure the nation’s biomedical research enterprise makes continued progress in lifesaving research and development.”

The NIH budget increase contained in the spending bill is, in fact, $714 million less than 2013’s “enacted level” of $30.648 billion, according to House Democrats. And the NIH itself reports that if the bill were to pass, the agency would be getting $950 million less than ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies